PE20161327A1 - Proteinas de enlace al antigeno il-23 humana - Google Patents

Proteinas de enlace al antigeno il-23 humana

Info

Publication number
PE20161327A1
PE20161327A1 PE2016002001A PE2016002001A PE20161327A1 PE 20161327 A1 PE20161327 A1 PE 20161327A1 PE 2016002001 A PE2016002001 A PE 2016002001A PE 2016002001 A PE2016002001 A PE 2016002001A PE 20161327 A1 PE20161327 A1 PE 20161327A1
Authority
PE
Peru
Prior art keywords
antigen
human
binding proteins
antibody
refers
Prior art date
Application number
PE2016002001A
Other languages
English (en)
Spanish (es)
Inventor
Heather Cerne
Janet D Cheng
Randal R Ketchem
Yu Zhang
Derek Evan Piper
Yu Sun
Jennifer E Towne
Jason Charles O'neill
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43413789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20161327(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PE20161327A1 publication Critical patent/PE20161327A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2016002001A 2009-10-26 2010-10-26 Proteinas de enlace al antigeno il-23 humana PE20161327A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25498209P 2009-10-26 2009-10-26
US38128710P 2010-09-09 2010-09-09

Publications (1)

Publication Number Publication Date
PE20161327A1 true PE20161327A1 (es) 2016-12-03

Family

ID=43413789

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2016002001A PE20161327A1 (es) 2009-10-26 2010-10-26 Proteinas de enlace al antigeno il-23 humana
PE2012000564A PE20121579A1 (es) 2009-10-26 2010-10-26 Proteinas de enlace al antigeno il-23 humanas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2012000564A PE20121579A1 (es) 2009-10-26 2010-10-26 Proteinas de enlace al antigeno il-23 humanas

Country Status (39)

Country Link
US (9) US8722033B2 (enExample)
EP (3) EP3656790A1 (enExample)
JP (5) JP5930968B2 (enExample)
KR (3) KR20160118278A (enExample)
CN (3) CN104761642A (enExample)
AR (1) AR078778A1 (enExample)
AU (1) AU2010315557B2 (enExample)
BR (2) BR122020002402B8 (enExample)
CA (2) CA3030092C (enExample)
CL (1) CL2012001096A1 (enExample)
CO (1) CO6531481A2 (enExample)
CR (1) CR20120210A (enExample)
CY (1) CY1118576T1 (enExample)
EA (1) EA025366B1 (enExample)
ES (1) ES2613236T3 (enExample)
HK (1) HK1212357A1 (enExample)
HR (1) HRP20170037T1 (enExample)
HU (1) HUE030871T2 (enExample)
IL (3) IL219241A (enExample)
JO (1) JO3244B1 (enExample)
LT (1) LT2493925T (enExample)
MA (1) MA33757B1 (enExample)
MX (1) MX358249B (enExample)
MY (1) MY156286A (enExample)
NZ (2) NZ599875A (enExample)
PE (2) PE20161327A1 (enExample)
PH (1) PH12012500771A1 (enExample)
PL (1) PL2493925T3 (enExample)
PT (1) PT2493925T (enExample)
RS (1) RS55666B1 (enExample)
SG (2) SG10202103260TA (enExample)
SI (1) SI2493925T1 (enExample)
SM (1) SMT201700069T1 (enExample)
TN (1) TN2012000167A1 (enExample)
TW (2) TW201417830A (enExample)
UA (1) UA113609C2 (enExample)
UY (1) UY32971A (enExample)
WO (1) WO2011056600A1 (enExample)
ZA (1) ZA201203058B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PT2635601T (pt) 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anticorpos anti-il-23
AU2012209455B2 (en) * 2011-01-25 2017-05-04 Monell Chemical Senses Center Compositions and methods for providing or modulating sweet taste and methods of screening therefor
EP2583979B1 (en) * 2011-10-19 2015-12-16 Effimune Methods to prepare antibodies directed against p19 subunit of human IL-23
EP4039275A1 (en) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
KR20150128858A (ko) * 2013-03-15 2015-11-18 암젠 인크 항-il-23 항체를 사용한 건선의 치료 방법
EP3693007A1 (en) * 2013-03-15 2020-08-12 Amgen, Inc Methods for treating crohn's disease using an anti-il23 antibody
KR20250066486A (ko) 2013-10-21 2025-05-13 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
PT3060908T (pt) 2013-10-21 2021-05-27 Dyax Corp Diagnóstico e tratamento de doenças autoimunes
US10272154B2 (en) 2014-04-15 2019-04-30 Sorrento Therapeutics, Inc. Antigen binding proteins that bind WISP1
WO2015179918A1 (en) 2014-05-27 2015-12-03 The University Of Queensland Modulation of cellular stress
EP3169710A1 (en) 2014-07-14 2017-05-24 Amgen Inc. Crystalline antibody formulations
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
EA039598B9 (ru) 2014-09-03 2022-03-10 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23а и фно-альфа, и его применение
IL307578A (en) 2015-02-04 2023-12-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases
HK1258292A1 (zh) 2015-09-17 2019-11-08 Amgen Inc. 使用il23途徑生物標誌物預測il23拮抗劑的臨床應答
TWI733695B (zh) * 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
DK3365685T3 (da) 2015-10-19 2021-03-01 Dyax Corp Immunoassay til påvisning af spaltet højmolekylært kininogen
RU2018124603A (ru) 2015-12-22 2020-01-24 Эмджен Инк. Ccl20 как прогностический фактор клинического ответа на антагонисты ил-23
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2019023811A1 (en) * 2017-08-04 2019-02-07 The Hospital For Sick Children NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY
WO2019023812A1 (en) * 2017-08-04 2019-02-07 The Hospital For Sick Children VACCINE COMPOSITION AGAINST MALARIA AND METHOD THEREOF
TWI837532B (zh) 2018-03-30 2024-04-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
AU2019300491A1 (en) * 2018-07-13 2021-03-04 Astrazeneca Collaboration Ventures, Llc Treating ulcerative colitis with brazikumab
GB201820687D0 (en) * 2018-12-19 2019-01-30 Kymab Ltd Antagonists
CA3142667A1 (en) * 2019-06-04 2020-12-10 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
AU2020308463A1 (en) 2019-06-26 2022-02-17 Ap Biosciences, Inc. Antibodies for T-cell activation
AU2020409124A1 (en) 2019-12-20 2022-06-30 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
CN112807428B (zh) * 2020-06-12 2024-08-27 江苏荃信生物医药股份有限公司 包含抗人白介素23单克隆抗体的药物组合物
WO2022041390A1 (zh) * 2020-08-28 2022-03-03 江苏荃信生物医药股份有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂及其制备方法
AR123477A1 (es) 2020-09-10 2022-12-07 Lilly Co Eli Formulaciones de anticuerpos terapéuticos
CN114773466B (zh) * 2020-11-26 2023-08-29 江苏荃信生物医药股份有限公司 一种抗人白介素23及包含其的试剂盒及其检测方法
US20220373539A1 (en) * 2021-05-24 2022-11-24 Amgen Inc. Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
EP4359444A4 (en) * 2021-06-25 2025-07-16 Sangamo Therapeutics Inc IL-23R-SPECIFIC ANTIGEN BINDERS AND THEIR USES
JP2024536166A (ja) 2021-09-30 2024-10-04 イーライ リリー アンド カンパニー 潰瘍性大腸炎における腸切迫感に関与する遺伝子の抗ｉｌ－２３ｐ１９抗体による調節
CN114994331B (zh) * 2022-05-17 2023-02-24 无锡科金生物科技有限公司 一种检测蛋白表达水平的试剂盒及其制备方法和应用
WO2024077113A1 (en) 2022-10-06 2024-04-11 Eli Lilly And Company Methods of treating fatigue in ulcerative colitis
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
CA2111348A1 (en) 1991-06-14 1992-12-23 John S. Logan Production of human hemoglobin in transgenic pigs
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
WO1993010227A1 (en) 1991-11-14 1993-05-27 Charles Weissmann Transgenic animals lacking prion proteins
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
CA2146559A1 (en) 1992-10-23 1994-05-11 Melanie K. Spriggs Methods of preparing soluble, oligomeric proteins
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
PE20000183A1 (es) 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
CA2324115C (en) * 1998-03-17 2008-12-23 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for inflammatory bowel disease comprising il-6 antagonist as an active ingredient
ATE474849T1 (de) 1998-04-14 2010-08-15 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
JP4505166B2 (ja) 1999-09-09 2010-07-21 シェーリング コーポレイション 哺乳動物インターロイキン−１２ｐ４０およびインターロイキンｂ３０、その組成物、抗体、薬学的組成物における使用
KR101053412B1 (ko) 2002-10-30 2011-08-01 제넨테크, 인크. Ｉｌ―１７ 생성의 억제
EP1587834B1 (en) 2002-12-23 2011-07-06 Schering Corporation Uses of il-23 mammalian cytokine; related reagents
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
BRPI0408247A (pt) 2003-03-10 2006-03-01 Schering Corp usos de antagonistas e agonistas de il-23 e reagentes relacionados
CA2525184C (en) 2003-05-09 2012-10-30 Centocor, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
US7501247B2 (en) 2004-05-03 2009-03-10 Schering Corporation Method of treating skin inflammation
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
US7820168B2 (en) 2004-12-20 2010-10-26 Schering Corporation Treatment of diabetes using antibodies to IL-23, IL-23 receptor and IL-17
AR051805A1 (es) 2004-12-21 2007-02-07 Centocor Inc Anticuerpos anti-il-12, epitopos, composiciones, metodos y usos
CN103145839A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
EP3501537A1 (en) * 2005-06-30 2019-06-26 Janssen Biotech, Inc. Anti-il23 antibodies, compositions, methods and uses
WO2007024846A2 (en) 2005-08-25 2007-03-01 Eli Lilly And Company Anit-il-23 antibiodies
SG165322A1 (en) * 2005-08-31 2010-10-28 Schering Corp Engineered anti-il-23 antibodies
CN1955248B (zh) 2005-10-28 2011-10-12 安集微电子（上海）有限公司 钽阻挡层用化学机械抛光浆料
CN101389769A (zh) 2005-12-28 2009-03-18 森托科尔公司 用于评价和治疗银屑病及相关疾病的标记与方法
JP5193881B2 (ja) 2005-12-29 2013-05-08 セントカー・インコーポレーテツド ヒト抗ｉｌ−２３抗体、組成物、方法および用途
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
AU2007260787A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
MX2009007570A (es) * 2007-01-16 2009-07-22 Abbott Lab Metodos para tratar la psoriasis.
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
US20100111966A1 (en) * 2007-02-23 2010-05-06 Schering Corporation Engineered anti-il-23p19 antibodies
BRPI0807710B1 (pt) * 2007-02-23 2021-12-14 Merck Sharp & Dohme Corp Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
EP2215125A1 (en) 2007-11-27 2010-08-11 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
JP2011515404A (ja) 2008-03-18 2011-05-19 アボット・ラボラトリーズ 乾癬を治療するための方法
KR101781965B1 (ko) 2008-08-14 2017-09-27 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
WO2010027766A1 (en) 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
JP2012522749A (ja) 2009-04-01 2012-09-27 グラクソ グループ リミテッド 抗ｉｌ−２３免疫グロブリン
EP2414546A4 (en) 2009-04-02 2013-03-13 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASE AND COLON CARCINOMA
EP2435480A1 (en) 2009-05-27 2012-04-04 Ablynx N.V. Biparatopic protein constructs directed against il-23
SG179135A1 (en) 2009-09-14 2012-05-30 Abbott Lab Methods for treating psoriasis
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EA201891433A3 (ru) 2010-01-15 2019-02-28 Кирин-Эмджен, Инк. Состав антитела и терапевтические режимы
BR112012019881A2 (pt) 2010-02-18 2017-06-27 Bristol Myers Squibb Co proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23
WO2012009760A1 (en) 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
AU2011311965A1 (en) 2010-10-06 2013-03-28 Abbvie Inc. Methods for treating psoriasis
WO2012045848A1 (en) 2010-10-08 2012-04-12 Novartis Ag Methods of treating psoriasis using il-17 antagonists
PT2635601T (pt) 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anticorpos anti-il-23
AU2012204237A1 (en) 2011-01-07 2013-07-04 Abbvie Inc. Anti-IL-12/IL-23 antibodies and uses thereof
EP3693007A1 (en) 2013-03-15 2020-08-12 Amgen, Inc Methods for treating crohn's disease using an anti-il23 antibody
HK1258292A1 (zh) 2015-09-17 2019-11-08 Amgen Inc. 使用il23途徑生物標誌物預測il23拮抗劑的臨床應答
RU2018124603A (ru) 2015-12-22 2020-01-24 Эмджен Инк. Ccl20 как прогностический фактор клинического ответа на антагонисты ил-23
AU2019300491A1 (en) 2018-07-13 2021-03-04 Astrazeneca Collaboration Ventures, Llc Treating ulcerative colitis with brazikumab
WO2021035129A1 (en) 2019-08-21 2021-02-25 Astrazeneca Collaboration Ventures, Llc Use of brazikumab to treat crohn's disease

Also Published As

Publication number Publication date
CA3030092C (en) 2023-12-19
JO3244B1 (ar) 2018-03-08
CN104761642A (zh) 2015-07-08
US8722033B2 (en) 2014-05-13
CA3030092A1 (en) 2011-05-12
MX358249B (es) 2018-08-10
US20220056122A1 (en) 2022-02-24
JP2013507991A (ja) 2013-03-07
US9951129B2 (en) 2018-04-24
TW201121567A (en) 2011-07-01
PT2493925T (pt) 2017-02-14
IL219241A0 (en) 2012-06-28
US20190071498A1 (en) 2019-03-07
MX2012004868A (es) 2012-08-03
US20210024626A1 (en) 2021-01-28
BR112012009854B1 (pt) 2020-12-15
CY1118576T1 (el) 2017-07-12
JP5930968B2 (ja) 2016-06-08
HK1212357A1 (en) 2016-06-10
SI2493925T1 (sl) 2017-05-31
CR20120210A (es) 2012-07-20
AU2010315557A1 (en) 2012-09-20
RS55666B1 (sr) 2017-06-30
KR101568461B1 (ko) 2015-11-12
WO2011056600A1 (en) 2011-05-12
HRP20170037T1 (hr) 2017-03-10
US12012449B2 (en) 2024-06-18
HUE030871T2 (en) 2017-06-28
JP2018117626A (ja) 2018-08-02
UY32971A (es) 2010-11-30
UA113609C2 (xx) 2017-02-27
BR122020002402B1 (pt) 2022-02-08
US20200181255A1 (en) 2020-06-11
TWI432210B (zh) 2014-04-01
PE20121579A1 (es) 2012-12-13
US20140212428A1 (en) 2014-07-31
CO6531481A2 (es) 2012-09-28
US9487580B2 (en) 2016-11-08
JP2022033730A (ja) 2022-03-02
EP2493925A1 (en) 2012-09-05
IL244801B (en) 2020-05-31
BR112012009854A2 (pt) 2016-11-22
CA2778112A1 (en) 2011-05-12
BR112012009854B8 (pt) 2021-05-25
PH12012500771A1 (en) 2012-11-26
EA025366B1 (ru) 2016-12-30
MA33757B1 (fr) 2012-11-01
KR20120090091A (ko) 2012-08-16
IL274871A (en) 2020-07-30
CA2778112C (en) 2019-02-26
PL2493925T3 (pl) 2017-09-29
EA201270571A1 (ru) 2012-09-28
JP7278355B2 (ja) 2023-05-19
NZ625630A (en) 2016-09-30
MY156286A (en) 2016-01-29
HK1177469A1 (en) 2013-08-23
ZA201203058B (en) 2013-01-30
KR20160118278A (ko) 2016-10-11
SG10201800682SA (en) 2018-03-28
JP7023908B2 (ja) 2022-02-22
CN102741285A (zh) 2012-10-17
KR20140062186A (ko) 2014-05-22
NZ599875A (en) 2014-10-31
BR122020002402B8 (pt) 2022-03-29
EP3656790A1 (en) 2020-05-27
CL2012001096A1 (es) 2012-09-28
AR078778A1 (es) 2011-11-30
BR112012009854A8 (pt) 2019-10-08
LT2493925T (lt) 2017-04-25
JP2020018308A (ja) 2020-02-06
CN110407936A (zh) 2019-11-05
US20190322737A1 (en) 2019-10-24
SMT201700069T1 (it) 2017-05-08
TW201417830A (zh) 2014-05-16
EP2493925B1 (en) 2016-11-23
US20130004501A1 (en) 2013-01-03
IL244801A0 (en) 2016-04-21
AU2010315557B2 (en) 2014-02-27
CN102741285B (zh) 2015-03-25
ES2613236T3 (es) 2017-05-23
KR101652609B1 (ko) 2016-08-30
IL219241A (en) 2016-03-31
US20170002070A1 (en) 2017-01-05
US20210230267A1 (en) 2021-07-29
SG10202103260TA (en) 2021-05-28
EP3181586A1 (en) 2017-06-21
JP2016102122A (ja) 2016-06-02
TN2012000167A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
PE20161327A1 (es) Proteinas de enlace al antigeno il-23 humana
CL2012000524A1 (es) Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo.
PE20142243A1 (es) Anticuerpos que se unen a ox40 y sus usos
PE20170772A1 (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de union a antigeno, una composicion farmaceutica y uso
CL2011002482A1 (es) Anticuerpo biespecificos que se une especificamente a las proteinas erbb-3 humana y c-met humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar cancer
EA201300256A1 (ru) Антитела к рецептору эпидермального фактора роста-3 (her3)
EA201690310A1 (ru) Антитела, связывающие cd27 человека, и их применение
MX382398B (es) Proteinas de union a antigeno st2.
EA201270769A1 (ru) Антитела к cgrp
PE20140633A1 (es) Anticuerpos neutralizadores anti-ccl20
CL2008002444A1 (es) Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
PE20131209A1 (es) Anticuerpos anti-fap
PE20170288A1 (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno
MX2011011754A (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b.
CL2013001279A1 (es) Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso.
CL2012000914A1 (es) Anticuerpos monoclonales que se unen especificamente a la region c-terminal de progastrina. uso para la preparacion de un medicamento util en el tratamiento de cancer colorectal.
ECSP14001260A (es) Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas
EA201591611A1 (ru) Конъюгаты антитело-лекарственное средство
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
EA201790664A1 (ru) Антитела против мезотелина и иммуноконъюгаты
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
CL2011002831A1 (es) Anticuerpo humanizado especifico de la forma protofibrilar del peptido a-beta; uso de dicho anticuerpo para tratar transtornos neurodegenerativos; composicion farmaceutica; celula que produce dichos anticuerpos; y procedimientos de preparacion de dicho anticuerpo.
EA201171374A1 (ru) Антитела против cd100 и способы их применения
UA114712C2 (uk) Моноклональне антитіло, яке імуноспецифічно зв'язується з людським psgl-1, та його застосування

Legal Events

Date Code Title Description
FA Abandonment or withdrawal